^
    Apply
    Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) (KEYNOTE E27) (NCT04956640)
    Phase 1/2
    Eli Lilly and Company
    Recruiting
    Last update posted :
    01/28/2025
    Initiation :
    07/19/2021
    Primary completion :
    06/01/2026
    Completion :
    06/01/2026
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • cisplatin • erlotinib • carboplatin • Tyvyt (sintilimab) • Verzenio (abemaciclib) • pemetrexed • batoprotafib (TNO155) • temuterkib (LY3214996) • LY3295668 • olomorasib (LY3537982)
    A Study of LY3537982 in Chinese Participants With Advanced Solid Tumors (NCT06235983)
    Phase 1
    Eli Lilly and Company
    Recruiting
    Last update posted :
    05/31/2024
    Initiation :
    02/29/2024
    Primary completion :
    01/01/2025
    Completion :
    01/01/2026
    KRAS
    |
    olomorasib (LY3537982)
    A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C (SUNRAY-01) (NCT06119581)
    Phase 3
    Eli Lilly and Company
    Recruiting
    Last update posted :
    05/29/2024
    Initiation :
    12/21/2023
    Primary completion :
    10/01/2026
    Completion :
    10/01/2029
    PD-L1 • KRAS
    |
    PD-L1 expression • KRAS mutation • KRAS G12C • KRAS G12
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • olomorasib (LY3537982)